Sarepta Therapeutics, Inc.
215 First Street
About Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. is at the forefront of precision genetic medicine, having built an impressive and competitive position in Duchenne muscular dystrophy(DMD), Limb-girdle muscular dystrophy (LGMD) and CNS. The Company has close to 30 programs in development across several therapeutic modalities, including RNA, gene therapy and gene editing.
Corporate Mission Statement:
Armed with the most advanced science in genetic medicine, we are in a daily race to rescue lives otherwise stolen by rare disease.
At Sarepta, every day is another 24 hours to stand up for patients, advance technology, challenge convention and drag tomorrow into today.
Stock Symbol: SRPT
Stock Exchange: NASDAQ
621 articles with Sarepta Therapeutics, Inc.
There are high hopes for more M&A in the industry for the remainder of the year. Here’s a look at the 10 top takeover targets.
SHAREHOLDER ALERT - Sarepta Therapeutics, Inc. (SRPT) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Deadline: October 29, 2019
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Sarepta securities between September 6, 2017 and August 19, 2019, both dates inclusive.
Although a definite blow to Sarepta, this may have negative implications for other companies working to develop therapies for DMD. This includes Wave Life Sciences and Solid Biosciences.
The regulatory agency expressed concern regarding the risk of infections related to intravenous infusion ports and renal toxicity seen in pre-clinical models of golodirsen and observed following administration of other antisense oligonucleotides, Sarepta said.
Wrapping up the month of August, there are technically four PDUFA dates on the calendar, although one was approved two months early and another may be delayed as the U.S. Food and Drug Administration reevaluates its policies regarding opioid pain medications. Here’s a look.
It was reported that a boy in Sarepta Therapeutics clinical trial for its micro-dystrophin gene therapy for Duchenne muscular dystrophy had a serious adverse event. However, the company indicates the adverse event report was submitted erroneously.
The company, best known for Exondys 51 (eteplirsen) for Duchenne muscular dystrophy (DMD), reported a net loss of $276.4 million for the quarter compared to a loss of $109.3 million in the same period in 2018. For the six-month period ending June 30, Sarepta reported a net loss of $353 million.
7/15/2019It was a typically busy week for clinical trials, with announcements in a wide variety of indications. Here’s a look.
7/10/2019All three studies found significant slowing of respiratory decline in the patients receiving Exondys 51 and it was consistent across all stages of the disease studied.
As the largest center for biotech startups in the U.S., the Boston/Cambridge, Massachusetts area often acts as a marker for the entire industry. Here’s a look at the Massachusetts M&A deals so far.
Sarepta struck a deal with the Research Institute at Nationwide Children’s Hospital for the gene therapy candidate, calpain 3.
Paragon announces its second GMP manufacturing facility and the expansion of its strategic collaboration in manufacturing design and operation with gene therapy leader Sarepta Therapeutics
With the Catalent transaction anticipated to close in 2Q 2019, the combined strengths of each organization will assure best manufacturing assets and unmatched operational excellence in one of the fastest-growing areas of healthcare
Cambridge, Mass.-based Sarepta Therapeutics announced data from its interim analysis of muscle biopsy endpoints of its therapy casimersen for Duchenne muscular dystrophy (DMD). The interim data was strong enough to support a probable New Drug Application (NDA) submission to the U.S. Food and Drug...
Agreement focused on identification of patients with Duchenne muscular dystrophy (DMD)
Companies to Exercise Purchase Option Agreement Following Positive, Preliminary Data in Limb-Girdle Muscular Dystrophy Type 2E Program
As part of the deal, Sarepta picks up five gene therapy candidates to treat distinct types of LGMD. The original deal was inked in May 2018, when the two companies partnered to develop five gene therapy compounds.
History shows just how slow public health officials, the federal government, regulators and pharmaceutical companies were to respond to the emergence of HIV in the 1980s. The reasons are numerous—it was a puzzling viral disease, it first appeared in what was then a largely stigmatized patient pop...
The JP Morgan Healthcare Conference, being held from January 7 through 10 at the Westin St. Francis Hotel in San Francisco, is one of the premier, possible the premier, conferences for the biopharmaceutical industry.
Sarepta Therapeutics Enters into Long-term Strategic Relationship with Aldevron for GMP-grade Plasmid in Support of Gene Therapy Development and Commercial Manufacturing Strategy
Agreement provides Sarepta with committed capacity and dedicated manufacturing slots for GMP-grade plasmid production for its micro-dystrophin Duchenne muscular dystrophy (DMD) gene therapy program, as well as plasmid capacity for future gene therapy programs
Sarepta Therapeutics Completes Submission of New Drug Application Seeking Approval of Golodirsen (SRP-4053) in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 53
-- Golodirsen has been studied for the treatment of exon 53 amenable patients, approximately eight percent of patients with Duchenne --